Equity Overview
Price & Market Data
Price: $5.85
Daily Change: +$0.20 / 3.42%
Daily Range: $0 - $0
Market Cap: $536,076,032
Daily Volume: 0
Performance Metrics
1 Week: -0.53%
1 Month: -18.94%
3 Months: 17.71%
6 Months: 43.77%
1 Year: 391.3%
YTD: 7.82%
Company Details
Employees: 40
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.